ELMD vs. LQDA, EMBC, PLSE, ESTA, FNA, EYE, BVS, AXGN, BFLY, and CBLL
Should you be buying Electromed stock or one of its competitors? The main competitors of Electromed include Liquidia (LQDA), Embecta (EMBC), Pulse Biosciences (PLSE), Establishment Labs (ESTA), Paragon 28 (FNA), National Vision (EYE), Bioventus (BVS), AxoGen (AXGN), Butterfly Network (BFLY), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Electromed vs.
Liquidia (NASDAQ:LQDA) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
64.5% of Liquidia shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 30.1% of Liquidia shares are owned by company insiders. Comparatively, 14.0% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Electromed has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Liquidia presently has a consensus price target of $25.38, indicating a potential upside of 77.76%. Given Liquidia's stronger consensus rating and higher probable upside, research analysts plainly believe Liquidia is more favorable than Electromed.
In the previous week, Electromed had 2 more articles in the media than Liquidia. MarketBeat recorded 4 mentions for Electromed and 2 mentions for Liquidia. Electromed's average media sentiment score of 1.85 beat Liquidia's score of 1.25 indicating that Electromed is being referred to more favorably in the news media.
Liquidia received 188 more outperform votes than Electromed when rated by MarketBeat users. However, 87.50% of users gave Electromed an outperform vote while only 68.24% of users gave Liquidia an outperform vote.
Electromed has a net margin of 11.34% compared to Liquidia's net margin of -765.38%. Electromed's return on equity of 15.32% beat Liquidia's return on equity.
Liquidia has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.
Summary
Electromed beats Liquidia on 11 of the 19 factors compared between the two stocks.
Get Electromed News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Electromed Competitors List
Related Companies and Tools
This page (NYSE:ELMD) was last updated on 1/23/2025 by MarketBeat.com Staff
Free ELMD Stock Alerts